Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517864 · ClinicalTrials.gov registry record · Phase 2
Placebo-controlled Safety Study OF Ritlecitinib (PF-06651600) IN Adults With Alopecia Areata
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT04517864 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 71 participants.
The verdict
NCT04517864, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
Interventions
- DRUG Placebo
- DRUG PF-06651600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04517864
The ClinicalTrials.gov registry entry for NCT04517864 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04517864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04517864 about?
NCT04517864 is a clinical study titled "Placebo-controlled Safety Study OF Ritlecitinib (PF-06651600) IN Adults With Alopecia Areata". This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
What is the current status of trial NCT04517864?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2020-09-15. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT04517864?
The interventions under investigation include: Placebo (DRUG), PF-06651600 (DRUG).
Who is sponsoring clinical trial NCT04517864?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.